*ST麥趣(002719.SZ):擬1390.60萬元轉讓紹興新美心95%股權
格隆匯12月14日丨*ST麥趣(002719.SZ)宣佈,公司於2020年12月12日召開了第三屆董事會第三十次會議,會議審議通過了《關於全資孫公司股權轉讓的議案》,同意全資子公司浙江新美心以1390.60萬元轉讓其持有全資子公司紹興新美心95%的股權。
紹興新美心為公司全資孫公司,主營業務為預包裝食品,乳製品。該次股權轉讓將優化公司資產結構,盤活存量資產,更好推進公司主營業務的發展,實現公司利益最大化。
該次股權轉讓完成後,浙江新美心將繼續持有紹興新美心5%的股權,獲得的資金將用於補充浙江新美心營運資金,符合浙江新美心長期發展戰略。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.